| Similar Articles |
|---|
 |
The Motley Fool
November 1, 2010
Brian Orelli |
Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect.   |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
August 9, 2011
Brian Orelli |
Give Avanir Some Time It's going to need it. |
Chemistry World
September 6, 2013
Phillip Broadwith |
Otsuka to buy Astex for $886 million Japanese firm Otsuka has agreed to buy the Anglo-American Astex Pharmaceuticals for $886 million in cash. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
January 31, 2011
Dan Dzombak |
5 Small-Cap Stocks on Fire These five watchlist stocks have been on fire lately: Capstone Turbine... Avanir Pharmaceuticals... Power-One... Oilsands Quest... FuelCell Energy... |
